TY - JOUR
T1 - Rituximab and chemotherapy for aggressive lymphomas
T2 - a significant advance in therapy.
AU - Hagemeister, Fredrick B.
N1 - Copyright:
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 2003/2
Y1 - 2003/2
N2 - Therapy with rituximab is the most important advance in the treatment of lymphomas since the development of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). Rituximab has single-agent activity in all types of B-cell lymphomas, including indolent and aggressive disease. For large-cell lymphomas, rituximab plus chemotherapy represents a significant advance over chemotherapy alone without significant added toxicity. Some studies report positive results using the antibody to treat other lymphomas. CHOP plus rituximab has become the standard of care.
AB - Therapy with rituximab is the most important advance in the treatment of lymphomas since the development of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). Rituximab has single-agent activity in all types of B-cell lymphomas, including indolent and aggressive disease. For large-cell lymphomas, rituximab plus chemotherapy represents a significant advance over chemotherapy alone without significant added toxicity. Some studies report positive results using the antibody to treat other lymphomas. CHOP plus rituximab has become the standard of care.
UR - http://www.scopus.com/inward/record.url?scp=33644621813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644621813&partnerID=8YFLogxK
M3 - Review article
C2 - 16224391
AN - SCOPUS:33644621813
SN - 1543-0790
VL - 1
SP - 120
EP - 125
JO - Clinical advances in hematology & oncology : H&O
JF - Clinical advances in hematology & oncology : H&O
IS - 2
ER -